Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : POZ-apomorphine
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Serina Therapeutics
Deal Size : Undisclosed
Deal Type : Merger
Serina Therapeutics Announces Completion of Merger with AgeX Therapeutics
Details : The combined company will focus on advancing pre-clinical studies of Serina’s lead drug candidate SER-252 (POZ-apomorphine) for treatment of Parkinson’s Disease, and expanding POZ Platform.
Product Name : SER-252
Product Type : Controlled Substance
Upfront Cash : Undisclosed
March 26, 2024
Lead Product(s) : POZ-apomorphine
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Serina Therapeutics
Deal Size : Undisclosed
Deal Type : Merger
Lead Product(s) : POZ-apomorphine
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Serina Therapeutics
Deal Size : Undisclosed
Deal Type : Merger
Serina Therapeutics and AgeX Therapeutics Enter into Merger Agreement
Details : The combined company will keep Serina name and trade on the New York Stock Exchange under the ticker "SER", and focus on advancing pre-clinical studies of Serina’s lead drug candidate SER-252 (POZ-apomorphine) for treatment of Parkinson’s Disease, an...
Product Name : SER-252
Product Type : Controlled Substance
Upfront Cash : Undisclosed
August 30, 2023
Lead Product(s) : POZ-apomorphine
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Serina Therapeutics
Deal Size : Undisclosed
Deal Type : Merger
Lead Product(s) : AgeX-BAT1
Therapeutic Area : Endocrinology
Study Phase : Preclinical
Sponsor : Ohio State University
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The Ohio State University will use AgeX’s brown adipocyte tissue (BAT) cell therapy candidate AgeX-BAT1 in mice to determine whether transplantation of AgeX-BAT1 cells may improve diet-induced obesity, metabolic health including glucose metabolism, and...
Product Name : AgeX-BAT1
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
October 03, 2021
Lead Product(s) : AgeX-BAT1
Therapeutic Area : Endocrinology
Highest Development Status : Preclinical
Sponsor : Ohio State University
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : AGEX-VASC1
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Preclinical
Sponsor : Lygenesis
Deal Size : Undisclosed
Deal Type : Termination
AgeX Therapeutics and LyGenesis Terminate Merger Negotiations
Details : AgeX has two preclinical cell therapy programs: AGEX-VASC1 (vascular progenitor cells) for tissue ischemia and AGEX-BAT1 (brown fat cells) for Type II diabetes.
Product Name : AGEX-VASC1
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
July 23, 2021
Lead Product(s) : AGEX-VASC1
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Preclinical
Sponsor : Lygenesis
Deal Size : Undisclosed
Deal Type : Termination
Lead Product(s) : IMS001
Therapeutic Area : Infections and Infectious Diseases
Study Phase : IND Enabling
Sponsor : ImStem Biotechnology
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : ImStem has obtained from AgeX a non-exclusive, royalty-bearing sublicense to use AgeX’s clinical-grade ESC line ESI-053 to derive ImStem’s investigational MSC product candidate IMS001 for development in COVID-19 as well as acute respiratory distress ...
Product Name : IMS001
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
October 28, 2020
Lead Product(s) : IMS001
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : IND Enabling
Sponsor : ImStem Biotechnology
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Recombinant Pluripotent Stem Cell-Derived Pancreatic Islet Beta Cell
Therapeutic Area : Endocrinology
Study Phase : Undisclosed
Sponsor : Sernova
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Sernova to utilize AgeX’s UniverCyteTM gene technology to generate transplantable, universal immune-protected therapeutic cells for Sernova’s Cell PouchTM Platform.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
May 29, 2020
Lead Product(s) : Recombinant Pluripotent Stem Cell-Derived Pancreatic Islet Beta Cell
Therapeutic Area : Endocrinology
Highest Development Status : Undisclosed
Sponsor : Sernova
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : IMS001
Therapeutic Area : Neurology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
ImStem Biotechnology Announces FDA has Lifted the Hold and Cleared IND for IMS001
Details : ImStem plans to initiate a phase 1 clinical study in patients with relapsing-remitting, secondary, and primary progressive forms of MS in 2020 in the US.
Product Name : IMS001
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
March 20, 2020
Lead Product(s) : IMS001
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Neural Stem Cell
Therapeutic Area : Genetic Disease
Study Phase : Undisclosed
Sponsor : University of California San Diego
Deal Size : Undisclosed
Deal Type : Collaboration
AgeX Therapeutics to Collaborate with University of California
Details : Program will utilize AgeX’s proprietary PureStem® cell derivation and manufacturing technology platform. Goal of developing cellular therapies for Huntington’s disease other neurological conditions.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
March 02, 2020
Lead Product(s) : Neural Stem Cell
Therapeutic Area : Genetic Disease
Highest Development Status : Undisclosed
Sponsor : University of California San Diego
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Hypoimmunogenic Cell
Therapeutic Area : Immunology
Study Phase : Discovery Platform
Sponsor : Undisclosed
Deal Size : Undisclosed
Deal Type : Collaboration
Details : First research collaboration for immunotolerance UniverCyteTM technology platform, marking launch of new business development and collaboration strategy.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
January 29, 2020
Lead Product(s) : Hypoimmunogenic Cell
Therapeutic Area : Immunology
Highest Development Status : Discovery Platform
Sponsor : Undisclosed
Deal Size : Undisclosed
Deal Type : Collaboration